News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Subscribe To Our Newsletter & Stay Updated
